Skip to main content
Clinical Trials/TCTR20210216004
TCTR20210216004
Completed
Not Applicable

tility of the enzyme-linked immunospot interferon-gamma-release assay to predict the risk of infection in kidney transplant recipients

Ramathibodi Hospital0 sites100 target enrollmentFebruary 16, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Infection in kidney transplant recipients
Sponsor
Ramathibodi Hospital
Enrollment
100
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 16, 2021
End Date
November 26, 2021
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • All kidney transplant recipients

Exclusion Criteria

  • Those who refused to join the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individualsCOVID-19
JPRN-UMIN000049834The Jikei University School of Medicine30
Active, not recruiting
Phase 4
rine Interferon Inducible Protein-10 Guided Treatment to Reduce Lupus Nephritis FlaresSystemic lupus erythemoatosus Lupus nephritisSystemic lupus erythemoatosusLupus nephritisUrine interferon inducible protein-10Preemptive immunosuppressive treatment
TCTR20190517004ational Science and Technology Development Agency216
Active, not recruiting
Phase 1
Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patientsSARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 daysMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862MedDRA version: 20.0Level: PTClassification code 10070255Term: Coronavirus test positiveSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-003872-42-ITIstituto di Farmacologia Traslazionale - CNR60
Completed
Not Applicable
Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4Hepatitis C virus (HCV)Infections and InfestationsChronic viral hepatitis
ISRCTN59358441Academic Medical Centre (AMC) (Netherlands)58
Recruiting
Not Applicable
Role and mechanism of type I interferon in the pathogenesis of anti-MDA5 antibody-positive dermatomyositisAnti-MDA5 antibody-positive dermatomyositis
JPRN-UMIN000049776Chiba University150